ABIVAX Société Anonyme (EPA:ABVX)
85.05
-1.15 (-1.33%)
Jun 19, 2026, 5:35 PM CET
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 80 employees as of March 31, 2026. The number of employees increased by 11 or 15.94% since the number was last reported on December 31, 2025.
Employees
80
Change
11
Growth
15.94%
Revenue / Employee
€61,500
Profits / Employee
€4,152,500
Market Cap
6.78B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 80 | 11 | 15.94% | 80 | 0 |
| Dec 31, 2025 | 69 | 0 | - | 69 | 0 |
| Dec 31, 2024 | 69 | 8 | 13.11% | 69 | 0 |
| Dec 31, 2023 | 61 | 37 | 154.17% | 61 | 0 |
| Dec 31, 2022 | 24 | 0 | - | 24 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Cellectis | 229 |
| Genfit | 188 |
| Innate Pharma | 164 |
| DBV Technologies | 161 |
| MedinCell | 145 |
| Transgene | 145 |
| Nanobiotix | 100 |
ABIVAX Société Anonyme News
- 3 days ago - ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 9 days ago - ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 11 days ago - ABVX DEADLINE: The Gross Law Firm Reminds ABIVAX Societe Anonyme Investors of Upcoming Securities Class Action Deadline - PRNewsWire
- 12 days ago - Abivax (ABVX) Faces Securities Fraud Investigation Amid Clinical Trial Concerns - GuruFocus
- 16 days ago - Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX) - Newsfile Corp
- 16 days ago - Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank - TheFly
- 16 days ago - Top Biotech Gainers: ABVX, CING, DRTS, MMED... - Nasdaq
- 17 days ago - This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead? - The Motley Fool